Japanese encephalitis virus prM-E antigen immunization conferred protection against challenge by four different serotypes of Dengue viruses in mice

被引:0
作者
Na Gao
Jieqiong Li
Ziyang Sheng
Hui Chen
Dongying Fan
Peigang Wang
Jing An
机构
[1] Capital Medical University,Department of Microbiology, School of Basic Medical Sciences
[2] Capital Medical University,Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Beijing Pediatric Research Institute, Beijing Children’s Hospital, National Center for Children’s Health
[3] Beijing Institute for Brain Disorders,Center of Epilepsy
来源
Applied Microbiology and Biotechnology | 2019年 / 103卷
关键词
Japanese encephalitis virus; Dengue virus; Flaviviruses; DNA vaccine; Cross-protection;
D O I
暂无
中图分类号
学科分类号
摘要
Dengue virus (DENV) and Japanese encephalitis virus (JEV) are closely related mosquito-borne flaviviruses. Together, they caused most arthropod-borne diseases in the world. Previously, we had demonstrated that both live attenuated and inactivated JE vaccines elicited cross-protection against DENV infection, and a DNA vaccine candidate expressing JEV prM-E protein (named pCAG-JME) could provide effective protection against JEV infection in mice. In this study, we examined whether the same pCAG-JME could elicit cross-protection against DENV infection. Our results showed that pCAG-JME indeed induced cross-reactive antibodies and cross-protection against four different serotypes of DENV in mice. Interestingly, pCAG-JME-immunized mice also generated both Th1 and Th2 responses when stimulated by all four different serotypes of DENV antigens. Moreover, cross-primed CD8+ T cell response was also detected following the stimulation of DENV proteins using intracellular cytokine staining. In addition, sera from pCAG-JME-immunized mice significantly reduced the mortality caused by DENV2 infection in severe combination immunodeficiency mouse. These results suggest that both JE and DENV cross-reactive antibodies and cross-primed T cells might play important roles in the cross-protection. The findings of this study also indicate a possibility of developing novel multivalent genetically engineered vaccines against both JEV and DENV.
引用
收藏
页码:4977 / 4986
页数:9
相关论文
共 331 条
  • [1] Aberle JH(2015)Addendum to report of the Global Advisory Committee on Vaccine Safety (GACVS), 10-11 June 2015(1). Safety of CYD-TDV dengue vaccine Wkly Epidemiol Rec 90 421-423
  • [2] Koblischke M(2018)CD4 T cell responses to flaviviruses J Clin Virol 108 126-131
  • [3] Stiasny K(2010)Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification PLoS Pathog 6 e1000790-507
  • [4] Balsitis SJ(2013)The global distribution and burden of dengue Nature 496 504-1365
  • [5] Williams KL(2014)Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial Lancet 384 1358-166
  • [6] Lachica R(2012)Suppressive effects on the immune response and protective immunity to a JEV DNA vaccine by co-administration of a GM-CSF-expressing plasmid in mice PLoS One 7 e34602-398
  • [7] Flores D(2016)Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice Sci Rep 6 30648-1174
  • [8] Kyle JL(2016)Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV(R)) in children Expert Rev Vaccines 15 153-748
  • [9] Mehlhop E(2011)Dengue vaccines: progress and challenges Curr Opin Immunol 23 391-35
  • [10] Johnson S(2007)A detailed mutagenesis study of flavivirus cross-reactive epitopes using West Nile virus-like particles J Gen Virol 88 1169-31